Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1

Interventions

Irinotecan 11Oxaliplatin 8Cetuximab 7Fluorouracil 6Leucovorin 5Bevacizumab 5Standard of Care 4S 1 (combination) 4Capecitabine 4trifluridine tipiracil drug combination 2tislelizumab 2apatinib 2Propranolol 2Preoperative Exercise 2Panitumumab 2Levoleucovorin 2Folfox protocol 2Etodolac 2Endoscopic Mucosal Resection 2Drug Therapy 2Chemotherapy, Adjuvant 2trebananib 1regorafenib 1envafolimab 1Trifluridine 1Thalidomide 1Surveys and Questionnaires 1Occult Blood 1Neoadjuvant Therapy 1Moxibustion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Colorectal Neoplasms × Etodolac × Clear all
NCT03919461 2019-04-18

COMPIT-2

Assaf-Harofeh Medical Center

Phase 2 Recruiting
200 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT00888797 2011-07-12

β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence

Sheba Medical Center

Phase 3 Unknown
400 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡